19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures.

Ask any pharma lobbyist: For all the talk of health policy being a national matter, it’s Brussels that holds major sway over drug prices. Intellectual property rights and incentives are a big factor, and some want the EU to play an even bigger role. 

A key piece of unfinished business from the outgoing European Commission is an effort to get EU countries to cooperate on so-called health technology assessment, the process by which policymakers decide how much money public health systems should pay for a new drug or treatment.

Read Politico article